Since the accelerated approval of atezolizumab in May 2016 [1], the U.S. Food and Drug Administration (FDA) has approved four additional programmed death receptor?1 (PD?1)/programmed death?ligand 1 (PD?L1) targeted immunotherapies for the treatment of patients with locally advanced or metastatic urothelial cancer. This includes the treatment of patients who have received prior platinum?containing chemotherapy as well as patients who are not eligible for cisplatin?containing chemotherapy.
